• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Nanomedicine shuts down cells that drive cancer growth in glioblastoma

July 12, 2017 By Sarah Faulkner

BrainResearchers from Northwestern Medicine have developed lipid polymer-based nanoparticles that target key cancer drivers, called brain tumor initiating cells, in a mouse model of glioblastoma brain tumors.

“BTICs are malignant brain tumor populations that underlie the therapy resistance, recurrence and unstoppable invasion commonly encountered by glioblastoma patients after the standard treatment regimen of surgical resection, radiation and chemotherapy,” first author Dr. Dou Yu said in prepared remarks.

The team’s study was published in the journal Proceedings of the National Academy of Sciences.

The researchers prepared mouse models of brain tumors using BTICs derived from human patients. Then, they injected small interfering RNA nanoparticles directly into the tumor. These short sequences of RNA limit the expression of cancer-promoting proteins, according to the researchers.

Part of what makes glioblastoma so challenging to treat is that its genetic makeup is different for each patient. The Northwestern team said its therapy could pave the way for personalized treatment, since siRNAs can target multiple cancer-causing gene products simultaneously.

The team evaluated siRNAs targeting four transcription factors that are expressed in many, but not all, glioblastoma tissues. They observed that the therapy was successful against glioblastoma BTICs with high levels of those four transcription factors, but other classes of the cancer did not respond.

In the preclinical model, the nanotechnology halted tumor growth and even extended survival after it was continuously administered using an implanted drug infusion pump.

“This major progress, although still at a conceptual stage, underscores a new direction in the pursuit of a cure for one of the most devastating medical conditions known to mankind,” Yu added.

The researchers stressed that this is an early, proof-of-concept study. They will need to evaluate its long-term safety before they can bring it into the clinic.

“This paints a picture for personalized glioblastoma therapy regimens based on tumor profiling,” Yu said. “Customized nanomedicine could target the unique genetic signatures in any specific patient and potentially lead to greater therapeutic benefits.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Nanoparticles, Neurological, Oncology, Research & Development Tagged With: Northwestern University

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS